Baxter Hlthcare Corp Drug Patent Portfolio

Baxter Hlthcare Corp owns 5 orange book drugs protected by 26 US patents with Clinolipid 20% having the least patent protection, holding only 1 patent. And Nouress with maximum patent protection, holding 19 patents. Given below is the list of Baxter Hlthcare Corp's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11173189 Daptomycin formulations containing a combination of sorbitol and mannitol 11 Mar, 2041
Active
US12097170 Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation 08 Mar, 2041
Active
US10493051 Cysteine composition and injection 15 Mar, 2039
Active
US10543186 Cysteine composition and injection 15 Mar, 2039
Active
US10702490 Cysteine composition and injection 15 Mar, 2039
Active
US11045438 Cysteine composition and injection 15 Mar, 2039
Active
US11510941 Stable, highly pure L-cysteine compositions for injection and methods of use 02 Mar, 2039
Active
US10478453 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10583155 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10653719 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10905713 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10905714 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10912795 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10918662 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US10933089 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US11510942 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US11642370 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US11648262 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US11679125 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US11684636 Stable, highly pure l-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US11826383 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
Active
US6900184 Compositions containing pipercillin and tazobactam useful for injection 14 Apr, 2023 Expired
US7915229 Compositions containing piperacillin and tazobactam useful for injection 14 Apr, 2023 Expired
US8133883 Compositions containing piperacillin and tazobactam useful for injection 14 Apr, 2023 Expired
US6207661 Premixed formulation of piperacillin sodium and tazobactam sodium injection 22 Feb, 2019 Expired
US5840757 Lipid emulsion intended for parenteral or enteral feeding 24 Nov, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Baxter Hlthcare Corp.

Activity Date Patent Number
Patent litigations
Expire Patent 15 Apr, 2024 US8133883
Mail O.P. Petition Decision 29 Dec, 2023 US10702490
Email Notification 29 Dec, 2023 US10702490
Mail-Record Petition Decision of Granted to Make Entity Status large 26 Dec, 2023 US10702490
Record Petition Decision of Granted to Make Entity Status large 22 Dec, 2023 US10702490
O.P. Petition Decision 22 Dec, 2023 US10702490
Payment of Maintenance Fee, 4th Year, Large Entity 01 Nov, 2023 US10653719
Maintenance Fee Reminder Mailed 30 Oct, 2023 US8133883
Petition Entered 16 Oct, 2023 US10702490
Payment of Maintenance Fee under 1.28(c) 16 Oct, 2023 US10702490
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 15 Oct, 2023 US10702490
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 11 Oct, 2023 US10702490
Payment of Maintenance Fee, 4th Yr, Small Entity 11 Oct, 2023 US10702490
Post Issue Communication - Certificate of Correction 27 Sep, 2023 US11510942
Payment of Maintenance Fee, 4th Year, Large Entity 23 Aug, 2023 US10583155


Baxter Hlthcare Corp's Drug Patent Litigations

Baxter Hlthcare Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US5840757. The petitioner , challenged the validity of this patent, with DUTOT as the respondent. Click below to track the latest information on how companies are challenging Baxter Hlthcare Corp's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11642370 February, 2024 Institution Denied
(08 Aug, 2024)
Exela Pharma Sciences, LLC Nexus Pharmaceuticals LLC
US10653719 September, 2020 Institution Denied
(23 Apr, 2021)
Exela Pharma Sciences LLC Eton Pharmaceuticals, Inc.
US10583155 June, 2020 Terminated-Denied
(15 Dec, 2020)
Exela Pharma Sciences, LLC Eton Pharmaceuticals Inc.
US10478453 May, 2020 Institution Denied
(18 Nov, 2020)
Exela Pharma Sciences, LLC Eton Pharmaceuticals, Inc.
US5840757 January, 1 Decision
(29 Jul, 1998)
DUTOT


Baxter Hlthcare Corp's Family Patents

Baxter Hlthcare Corp drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 42.5% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Baxter Hlthcare Corp Drug List

Given below is the complete list of Baxter Hlthcare Corp's drugs and the patents protecting them.


1. Clinolipid 20%

Clinolipid 20% is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5840757 Lipid emulsion intended for parenteral or enteral feeding 24 Nov, 2015
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clinolipid 20%'s drug page


2. Dapzura Rt

Dapzura Rt is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11173189 Daptomycin formulations containing a combination of sorbitol and mannitol 11 Mar, 2041
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dapzura Rt's drug page


3. Norepinephrine Bitartrate In 5% Dextrose

Norepinephrine Bitartrate In 5% Dextrose is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12097170 Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation 08 Mar, 2041
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norepinephrine Bitartrate In 5% Dextrose's drug page


4. Nouress

Nouress is protected by 19 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10493051 Cysteine composition and injection 15 Mar, 2039
(14 years from now)
Active
US10543186 Cysteine composition and injection 15 Mar, 2039
(14 years from now)
Active
US10702490 Cysteine composition and injection 15 Mar, 2039
(14 years from now)
Active
US11045438 Cysteine composition and injection 15 Mar, 2039
(14 years from now)
Active
US11510941 Stable, highly pure L-cysteine compositions for injection and methods of use 02 Mar, 2039
(14 years from now)
Active
US10478453 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10583155 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10653719 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10905713 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10905714 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10912795 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10918662 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US10933089 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US11510942 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US11642370 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US11648262 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US11679125 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US11684636 Stable, highly pure l-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active
US11826383 Stable, highly pure L-cysteine compositions for injection and methods of use 15 Jan, 2039
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nouress's drug page


5. Zosyn In Plastic Container

Zosyn In Plastic Container is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6900184 Compositions containing pipercillin and tazobactam useful for injection 14 Apr, 2023
(1 year, 6 months ago)
Expired
US7915229 Compositions containing piperacillin and tazobactam useful for injection 14 Apr, 2023
(1 year, 6 months ago)
Expired
US8133883 Compositions containing piperacillin and tazobactam useful for injection 14 Apr, 2023
(1 year, 6 months ago)
Expired
US6207661 Premixed formulation of piperacillin sodium and tazobactam sodium injection 22 Feb, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zosyn In Plastic Container's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List